Active Ingredient History
Bisoprolol is a cardioselective beta1-adrenergic blocking agent. It lower the heart rate and blood pressure and may be used to reduce workload on the heart and hence oxygen demands. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. Bisoprolol can be used to treat cardiovascular diseases such as hypertension, coronary heart disease, arrhythmias, ischemic heart diseases, and myocardial infarction after the acute event. General side effects are: fatigue, asthenia, chest pain, malaise, edema, weight gain, angioedema. Concurrent use of rifampin increases the metabolic clearance of bisoprolol fumarate, shortening its elimination half-life. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Angina, Stable (Phase 4)
Aortic Aneurysm, Abdominal (Phase 1)
Aortic Valve Stenosis (Phase 4)
Atrial Fibrillation (Phase 4)
Blood Loss, Surgical (Phase 1)
Blood Pressure (Phase 4)
Breast Neoplasms (Phase 3)
Cardiomyopathy, Dilated (Phase 2/Phase 3)
Cardiotoxicity (Phase 3)
Cardiovascular Diseases (Phase 3)
Chagas Cardiomyopathy (Phase 3)
Coronary Artery Bypass (Phase 4)
Coronary Artery Disease (Phase 4)
Diabetes Mellitus (Phase 2/Phase 3)
Diabetes Mellitus, Type 2 (Phase 4)
Essential Hypertension (Phase 4)
Familial Primary Pulmonary Hypertension (Phase 1/Phase 2)
Fasting (Phase 1)
General Surgery (Phase 1)
Healthy Volunteers (Phase 1)
Heart Diseases (Phase 4)
Heart Failure (Phase 4)
Heart Rate (Early Phase 1)
Hypertension (Phase 4)
Hypertension, Renal (Phase 4)
Insulin Resistance (Phase 4)
Metabolic Syndrome (Phase 4)
Muscular Dystrophy, Duchenne (Phase 2/Phase 3)
Myocardial Infarction (Phase 4)
Non-ST Elevated Myocardial Infarction (Phase 4)
Pharmacogenetics (Phase 4)
Pharmacokinetics (Phase 1)
Pheochromocytoma (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 4)
ST Elevation Myocardial Infarction (Phase 4)
Ventricular Dysfunction, Left (Phase 4)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue